Lichenoid dermatitis induced by abemaciclib in a patient with HR+/HER2- breast cancer

• Auteurs principaux: Edoardo Mortato (Auteur), Anna Paola De Caro (Auteur), Luca Schinzari (Auteur), Sonia Maniglio (Auteur), Carmelo Laface (Auteur), Gerardo Cazzato (Auteur), Caterina Foti (Auteur), Francesca Ambrogio (Auteur)
• Format: Livre
• Publié: PAGEPress Publications, 2024-11-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Cyclin-dependent kinase (CDK) 4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, are widely used in combination with endocrine therapy for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Despite their efficacy,...